{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:49:32Z","timestamp":1774374572962,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ahj.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T21:59:09Z","timestamp":1550699949000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation"],"prefix":"10.1016","volume":"212","author":[{"given":"Eric D.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.02.001_bb0005","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.02.001_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2015.04.004","article-title":"Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies","volume":"1","author":"Wong","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/eurheartj\/ehv486","article-title":"The role of obesity in atrial fibrillation","volume":"37","author":"Nalliah","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.02.001_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacep.2015.12.001","article-title":"Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF Registry","volume":"2","author":"Pandey","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0025","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.02.001_bb0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2019.02.001_bb0045","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.amjmed.2017.05.011","article-title":"Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban","volume":"130","author":"Moore","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2019.02.001_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5603\/CJ.a2015.0054","article-title":"The use of anticoagulants in morbidly obese patients","volume":"23","author":"Domienik-Kar\u0142owicz","year":"2016","journal-title":"Cardiol J"},{"key":"10.1016\/j.ahj.2019.02.001_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11239-012-0811-x","article-title":"Comparison of initial warfarin response in obese patients versus non-obese patients","volume":"36","author":"Wallace","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2019.02.001_bb0060","series-title":"Prescribing information","article-title":"Xarelto\u00ae (rivaroxaban) tablets, for oral use","year":"2017"},{"key":"10.1016\/j.ahj.2019.02.001_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials","volume":"48","author":"Proietti","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2019.02.001_bb0075","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ahj.2019.02.001_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2019.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2019.02.001_bb0095","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ahj.2019.02.001_bb0100","series-title":"Presented at the European Society of Cardiology Congress, Barcelona, Spain; 26-30 August 2017. P87116","article-title":"Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry","author":"Goldhaber","year":"2017"},{"key":"10.1016\/j.ahj.2019.02.001_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13012-017-0620-x","article-title":"Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics","volume":"12","author":"Barnes","year":"2017","journal-title":"Implement Sci"},{"key":"10.1016\/j.ahj.2019.02.001_bb0110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12325-015-0189-1","article-title":"Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users","volume":"32","author":"Laliberte","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.ahj.2019.02.001_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1472-6963-14-70","article-title":"Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies","volume":"14","author":"Martin","year":"2014","journal-title":"BMC Health Serv Res"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:15Z","timestamp":1757570535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319300225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"alternative-id":["S0002870319300225"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.02.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Janssen Scientific Affairs, LLC. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}